TGF-β3 and cancer: A review

Cytokine and Growth Factor Reviews

Volumn 20, Issue 4, 2009, Pages 305-317

  Laverty, H G ^a   Wakefield, L M ^b   Occleston, N L ^a   O'Kane, S ^a   Ferguson, M W J ^a  

^a Renovo   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Avotermin; Cytokines; Transforming growth factor ; Tumourigenesis

Indexed keywords

AVOTERMIN; ESTROGEN; GESTAGEN; MESSENGER RNA; ORAL CONTRACEPTIVE AGENT; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; ISOPROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; COLON CARCINOMA; DESMOPLASTIC SMALL ROUND CELL TUMOR; GENE EXPRESSION; HUMAN; MALIGNANT FIBROUS HISTIOCYTOMA; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OVARY CARCINOMA; PARITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK REDUCTION; SCAR FORMATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; SKIN INJURY; STOMACH CARCINOMA; TRANSCRIPTOMICS; UTERUS MYOMA; WOUND HEALING; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN ISOFORMS; SEQUENCE HOMOLOGY, AMINO ACID; TRANSFORMING GROWTH FACTOR BETA3;

EID: 69249206495     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2009.07.002     Document Type: Review

References (163)

1. Wakefield L.M., Letterio J.J., Geiser A.G., Flanders K.C., O'Shaughnessy J., Roberts A.B., et al. Transforming growth factor-beta s in mammary tumorigenesis: promoters or antipromoters?. Prog Clin Biol Res 391 (1995) 133-148
2. Gold L.I. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 10 (1999) 303-360
3. Padgett R.W. TGFbeta signaling pathways and human diseases. Cancer Metastasis Rev 18 (1999) 247-259
4. Prud'homme G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87 (2007) 1077-1091
5. Massague J. TGFβ in cancer. Cell 134 (2008) 215-230
6. Tang B., Vu M., Booker T., Santner S.J., Miller F.R., Anver M.R., et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112 (2003) 1116-1124
7. Tian F., DaCosta Byfield S., Parks W.T., Yoo S., Felici A., Tang B., et al. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 63 (2003) 8284-8292
8. Roberts A.B., and Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100 (2003) 8621-8623
9. De Crescenzo G., Hinck C.S., Shu Z., Zúñiga J., Yang J., Tang Y., et al. Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor. J Mol Biol 355 (2006) 47-62
10. Lyons R.M., Miller D.A., Graycar J.L., Moses H.L., and Derynck R. Differential binding of transforming growth factor-beta 1, -beta 2, and -beta 3 by fibroblasts and epithelial cells measured by affinity cross-linking of cell surface receptors. Mol Endocrinol 5 (1991) 1887-1896
11. Mitchell E.J., and O'Connor-McCourt M.D. A transforming growth factor beta (TGF-beta) receptor from human placenta exhibits a greater affinity for TGF-beta 2 than for TGF-beta 1. Biochemistry 30 (1991) 4350-4356
12. Lopez-Casillas F., Wrana J.L., and Massagué J. β-glycan presents ligand to the TGFβ signaling receptor. Cell 73 (1993) 1435-1444
13. Hinck A.P., Archer S.J., Qian S.W., Roberts A.B., Sporn M.B., Weatherbee J.A., et al. Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. Biochemistry 35 (1996) 8517-8534
14. Bocharov E.V., Blommers M.J., Kuhla J., Arvinte T., Bürgi R., and Arseniev A.S. Sequence-specific 1H and 15N assignment and secondary structure of transforming growth factor beta3. J Biomol NMR 16 (2000) 179-180
15. Bocharov E.V., Korzhnev D.M., Blommers M.J., Arvinte T., Orekhov V.Y., Billeter M., et al. Dynamics-modulated biological activity of transforming growth factor beta3. J Biol Chem 277 (2002) 46273-46279
16. Grütter C., Wilkinson T., Turner R., Podichetty S., Finch D., McCourt M., et al. A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc Natl Acad Sci USA 105 (2008) 20251-20256
17. Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., and Hinck A.P. Crystal structure of the human TbetaR2 ectodomain-TGF-beta3 complex. Nat Struct Biol 9 (2002) 203-208
18. Akhurst R.J., Lehnert S.A., Faissner A., and Duffie E. TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 108 (1990) 645-656
19. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S., and Akhurst R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121 (1995) 1845-1854
20. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693-699
21. Sanford L.P., Ormsby I., Gittenberger-de Groot A.C., Sariola H., Friedman R., Boivin G.P., et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124 (1997) 2659-2670
22. Proetzel G., Pawlowski S.A., Wiles M.V., Yin M., Boivin G.P., Howles P.N., et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 11 (1995) 409-414
23. Kaartinen V., Voncken J.W., Shuler C., Warburton D., Bu D., Heisterkamp N., et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11 (1995) 415-421
24. Fitzpatrick D.R., Denhez F., Kondaiah P., and Akhurst R.J. Differential expression of TGF beta isoforms in murine palatogenesis. Development 109 (1990) 585-595
25. Brunet C.L., Sharpe P.M., and Ferguson M.W. Inhibition of TGF-beta 3 (but not TGF-beta 1 or TGF-beta 2) activity prevents normal mouse embryonic palate fusion. Int J Dev Biol 39 (1995) 345-355
26. Taya Y., O'Kane S., and Ferguson M.W. Pathogenesis of cleft palate in TGF-beta3 knockout mice. Development 126 (1999) 3869-3879
27. Yang L.T., and Kaartinen V. Tgfb1 expressed in the Tgfb3 locus partially rescues the cleft palate phenotype of Tgfb3 null mutants. Dev Biol 312 (2007) 384-389
28. Ferguson M.W., and O'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 359 (2004) 839-850
29. Whitby D.J., and Ferguson M.W. Immunohistochemical localization of growth factors in fetal wound healing. Dev Biol 147 (1991) 207-215
30. Whitby D.J., and Ferguson M.W. The extracellular matrix of lip wounds in fetal, neonatal and adult mice. Development 112 (1991) 651-668
31. Shah M., Foreman D.M., and Ferguson M.W. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 339 (1992) 213-214
32. Shah M., Foreman D.M., and Ferguson M.W. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 107 (1994) 1137-1157
33. Shah M., Foreman D.M., and Ferguson M.W. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108 (1995) 985-1002
34. Ferguson M.W., Duncan J., Bond J., Bush J., Durani P., So K., et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 373 (2009) 1264-1274
35. Roberts A.B., and Sporn M.B. Transforming growth factors. Cancer Surv 4 (1985) 683-705
36. Wakefield L.M., and Sporn M.B. Suppression of carcinogenesis: a role for TGF-beta and related molecules in prevention of cancer. Immunol Ser 51 (1990) 217-243
37. Wakefield L.M., and Roberts A.B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12 (2002) 22-29
38. de Caestecker M.P., Piek E., and Roberts A.B. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92 (2000) 1388-1402
39. Akhurst R.J., and Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 11 (2001) S44-51
40. Miyazono K., and Heldin C.H. Latent forms of TGF-beta: molecular structure and mechanisms of activation. Ciba Found Symp 157 (1991) 81-89
41. Lawrence D.A. Latent-TGF-beta: an overview. Mol Cell Biochem 219 (2001) 163-170
42. Annes J.P., Munger J.S., and Rifkin D.B. Making sense of latent TGFbeta activation. J Cell Sci 116 (2003) 217-224
43. Chin L., Merlino G., and DePinho R.A. Malignant melanoma: modern black plague and genetic black box. Genes Dev 12 (1998) 3467-3481
44. Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
45. Elliott R.L., and Blobe G.C. Role of transforming growth factor Beta in human cancer. J Clin Oncol 23 (2005) 2078-2093
46. Heredia A., Villena J., Romarís M., Molist A., and Bassols A. The effect of TGF-beta 1 on cell proliferation and proteoglycan production in human melanoma cells depends on the degree of cell differentiation. Cancer Lett 109 (1996) 39-47
47. Krasagakis K., Garbe C., Schrier P.I., and Orfanos C.E. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res 14 (1994) 2565-2571
48. Roberts A.B., Anzano M.A., Wakefield L.M., Roche N.S., Stern D.F., and Sporn M.B. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 82 (1985) 119-123
49. Hennings H., Shores R., Mitchell P., Spangler E.F., and Yuspa S.H. Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis 6 (1985) 1607-1610
50. Akhurst R.J., and Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol 187 (1999) 82-90
51. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29 (2001) 117-129
52. Cui W., Fowlis D.J., Bryson S., Duffie E., Ireland H., Balmain A., et al. TGF-beta 1 inhibits the formation of benign skin tumours but enhances progression to invasive spindle cell carcinomas in transgenic mice. Cell 86 (1996) 531-542
53. Gold L.I., Jussila T., Fusenig N.E., and Stenback F. TGF-beta isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis. J Pathol 190 (2000) 579-588
54. Gallagher W.M., Bergin O.E., Rafferty M., Kelly Z.D., Nolan I.M., Fox E.J., et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26 (2005) 1856-1867
55. Egan K.M., Seddon J.M., Glynn R.J., Gragoudas E.S., and Albert D.M. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32 (1988) 239-251
56. Tschentscher F., Hüsing J., Hölter T., Kruse E., Dresen I.G., Jöckel K.H., et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 63 (2003) 2578-2584
57. Onken M.D., Ehlers J.P., Worley L.A., Makita J., Yokota Y., and Harbour J.W. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 66 (2006) 4602-4609
58. Onken M.D., Lin A.Y., Worley L.A., Folberg R., and Harbour J.W. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol 140 (2005) 748-749
59. Onken M.D., Worley L.A., Ehlers J.P., and Harbour J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64 (2004) 7205-7209
60. Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19 (2006) 290-302
61. Quigley D.A., To M.D., Pérez-Losada J., Pelorosso F.G., Mao J.H., Nagase H., et al. Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature 458 (2009) 505-508
62. Albino A.P., Davis B.M., and Nanus D.M. Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res 51 (1991) 4815-4820
63. Rodeck U., Bossler A., Graeven U., Fox F.E., Nowell P.C., Knabbe C., et al. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54 (1994) 575-581
64. MacDougall J.R., Kobayashi H., and Kerbel R.S. Responsiveness of normal dysplastic melanocytes and melanoma cells from different lesional stages of disease progression to the growth inhibitory effects of TGF-b. Mol Cell Different 1 (1993) 21-40
65. Schmid P., Itin P., and Rufli T. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 16 (1995) 1499-1503
66. Van Belle P., Rodeck U., Nuamah I., Halpern A.C., and Elder D.E. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 148 (1996) 1887-1894
67. Kawakami T., Soma Y., Mizoguchi M., and Saito R. Overexpression of transforming growth factor-beta3 immunohistochemical staining in extramammary Paget's disease, but downregulated expression in Bowen's disease. Int J Dermatol 40 (2001) 262-267
68. Rodeck U., Nishiyama T., and Mauviel A. Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res 59 (1999) 547-550
69. Chen D., Xu W., Bales E., Colmenares C., Conacci-Sorrell M., Ishii S., et al. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 63 (2003) 6626-6634
70. Schmid P., Cox D., Bilbe G., McMaster G., Morrison C., Stähelin H., et al. TGF-beta s and TGF-beta type II receptor in human epidermis: differential expression in acute and chronic skin wounds. J Pathol 171 (1993) 191-197
71. Dawson P.J., Wolman S.R., Tait L., Heppner G.H., and Miller F.R. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148 (1996) 313-319
72. Santner S.J., Dawson P.J., Tait L., Soule H.D., Eliason J., Mohamed A.N., et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65 (2001) 101-110
73. Forrester E., Chytil A., Bierie B., Aakre M., Gorska A.E., Sharif-Afshar A.R., et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 65 (2005) 2296-2302
74. Tu W.H., Thomas T.Z., Masumori N., Bhowmick N.A., Gorska A.E., Shyr Y., et al. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 5 (2003) 267-277
75. Biswas S., Chytil A., Washington K., Romero-Gallo J., Gorska A.E., Wirth P.S., et al. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 64 (2004) 4687-4692
76. Dickson R.B., Kasid A., Huff K.K., Bates S.E., Knabbe C., Bronzert D., et al. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84 (1987) 837-841
77. Arteaga C.L., Hurd S.D., Winnier A.R., Johnson M.D., Fendly B.M., and Forbes J.T. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 92 (1993) 2569-2576
78. Dumont N., and Arteaga C.L. Transforming growth factor-beta and breast cancer: tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2 (2000) 125-132
79. Benson J.R., Wakefield L.M., Baum M., and Colletta A.A. Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Br J Cancer 74 (1996) 352-358
80. Chakravarthy D., Green A.R., Green V.L., Kerin M.J., and Speirs V. Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. Int J Oncol 15 (1999) 187-194
81. Kakonen S.M., Selander K.S., Chirgwin J.M., Yin J.J., Burns S., Rankin W.A., et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277 (2002) 24571-24578
82. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103 (1999) 197-206
83. Lebrecht A., Grimm C., Euller G., Ludwig E., Ulbrich E., Lantzsch T., et al. Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast. Int J Biol Markers 19 (2004) 236-239
84. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
85. Bueno-de-Mesquita J.M., Linn S.C., Keijzer R., Wesseling J., Nuyten D.S., van Krimpen C., et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat September (2008)
86. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
87. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518-524
88. Koli K., Saharinen J., Hyytiainen M., Penttinen C., and Keski-Oja J. Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 52 (2001) 354-362
89. Padua D., Zhang X.H., Wang Q., Nadal C., Gerald W.L., Gomis R.R., et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133 (2008) 66-77
90. Bittner M. Expression project for oncology - breast samples. International Genomics Consortium, Phoeniz, AZ 85004. https://expo.intgen.org/expo/public/; 2005.
91. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102 (2005) 13550-13555
92. Ivshina A.V., George J., Senko O., Mow B., Putti T.C., Smeds J., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66 (2006) 10292-10301
93. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
94. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., et al. TRANSBIG consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 (2007) 3207-3214
95. Li C., Wang J., Wilson P.B., Kumar P., Levine E., Hunter R.D., et al. Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer. Int J Cancer 79 (1998) 455-459
96. Ghellal A., Hayes M., Byrne G., Bundred N., and Kumar S. Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 20 (2000) 4413-4418
97. Amatschek S., Koenig U., Auer H., Steinlein P., Pacher M., Gruenfelder A., et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64 (2004) 844-856
98. Soufla G., Porichis F., Sourvinos G., Vassilaros S., and Spandidos D.A. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. Cancer Lett 235 (2006) 100-113
99. Lambe M., Hsieh C.C., Chan H.W., Ekbom A., Trichopoulos D., and Adami H.O. Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Treat 38 (1996) 305-311
100. Russo J., and Russo I.H. Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. Cancer Res 40 (1980) 2677-2687
101. Russo J., Tay L.K., and Russo I.H. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2 (1982) 5-73
102. Welsch C.W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 45 (1985) 3415-3443
103. Sinha D.K., Pazik J.E., and Dao T.L. Prevention of mammary carcinogenesis in rats by pregnancy: effect of full-term and interrupted pregnancy. Br J Cancer 57 (1988) 390-394
104. Kelsey J.L., Gammon M.D., and John E.M. Reproductive factors and breast cancer. Epidemiol Rev 15 (1993) 36-47
105. Swanson S.M., Whitaker L.M., Stockard C.R., Myers R.B., Oelschlager D., Grizzle W.E., et al. Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancer. Anticancer Res 17 (1997) 4639-4645
106. Yang J., Yoshizawa K., Nandi S., and Tsubura A. Protective effects of pregnancy and lactation against N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. Carcinogenesis 20 (1999) 623-628
107. Rajkumar L., Guzman R.C., Yang J., Thordarson G., Talamantes F., and Nandi S. Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci USA 98 (2001) 11755-11759
108. Russo J., and Russo I.H. DNA labeling index and structure of the rat mammary gland as determinants of its susceptibility to carcinogenesis. J Natl Cancer Inst 61 (1978) 1451-1459
109. Russo J., Wilgus G., and Russo I.H. Susceptibility of the mammary gland to carcinogenesis. I. Differentiation of the mammary gland as determinant of tumor incidence and type of lesion. Am J Pathol 96 (1979) 721-736
110. Tay L.K., and Russo J. 7,12-dimethylbenz[a]anthracene-induced DNA binding and repair synthesis in susceptible and nonsusceptible mammary epithelial cells in culture. J Natl Cancer Inst 67 (1981) 155-161
111. Tay L.K., and Russo J. Formation and removal of 7,12-dimethylbenz[a]anthracene-nucleic acid adducts in rat mammary epithelial cells with different susceptibility to carcinogenesis. Carcinogenesis 2 (1982) 1327-1333
112. Russo I.H., and Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104 (1996) 938-967
113. D'Cruz C.M., Moody S.E., Master S.R., Hartman J.L., Keiper E.A., Imielinski M.B., et al. Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol 16 (2002) 2034-2051
114. Engle S.J., Hoying J.B., Boivin G.P., Ormsby I., Gartside P.S., and Doetschman T. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59 (1999) 3379-3386
115. Zhu Y., Richardson J.A., Parada L.F., and Graff J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94 (1998) 703-714
116. Bellone G., Carbone A., Tibaudi D., Mauri F., Ferrero I., Smirne C., et al. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer 37 (2001) 224-233
117. Vagenas K., Spyropoulos C., Gavala V., and Tsamandas A.C. TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J Surg Res 139 (2007) 182-188
118. Booth D., and Potten C.S. Protection against mucosal injury by growth factors and cytokines. J Natl Cancer Inst Monogr 29 (2001) 16-20
119. Schrementi M.E., Ferreira A.M., Zender C., and Dipietro L.A. Site-specific production of TGF-beta in oral mucosal and cutaneous wounds. Wound Repair Regen 16 (2008) 80-86
120. Bristow R.E., Baldwin R.L., Yamada S.D., Korc M., and Karlan B.Y. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer 85 (1999) 658-668
121. Inan S., Vatansever S., Celik-Ozenci C., Sanci M., Dicle N., and Demir R. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol Histopathol 21 (2006) 1055-1064
122. Rosenberg L., Zhang Y., Coogan P.F., Strom B.L., and Palmer J.R. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139 (1994) 654-661
123. Rodriguez G.C., Nagarsheth N.P., Lee K.L., Bentley R.C., Walmer D.K., Cline M., et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 94 (2002) 50-60
124. Parada D., Arciniegas E., Moreira O., and Trujillo E. Transforming growth factor-beta2 and beta3 expression in carcinoma of the prostate. Arch Esp Urol 57 (2004) 93-99
125. Djonov V., Ball R.K., Graf S., Mottaz A.E., Arnold A.M., Flanders K., et al. Transforming growth factor-beta 3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma. Prostate 31 (1997) 103-109
126. Luo J., Dunn T., Ewing C., Sauvageot J., Chen Y., Trent J., et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51 (2002) 189-200
127. Chetcuti A., Margan S., Mann S., Russell P., Handelsman D., Rogers J., et al. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate 47 (2001) 132-140
128. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
129. Vanaja D.K., Cheville J.C., Iturria S.J., and Young C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 63 (2003) 3877-3882
130. Liu P., Ramachandran S., Ali Seyed M., Scharer C.D., Laycock N., Dalton W.B., et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66 (2006) 4011-4019
131. Tomlins S.A., Rubin M.A., and Chinnaiyan A.M. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39 (2007) 41-51
132. Kloen P., Gebhardt M.C., Perez-Atayde A., Rosenberg A.E., Springfield D.S., Gold L.I., et al. Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression. Cancer 80 (1997) 2230-2239
133. Yang R.S., Wu C.T., Lin K.H., Hong R.L., Liu T.K., and Lin K.S. Relation between histological intensity of transforming growth factor-beta isoforms in human osteosarcoma and the rate of lung metastasis. Tohoku J Exp Med 184 (1998) 133-142
134. Grainger D.J., Percival J., Chiano M., and Spector T.D. The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporos Int 9 (1999) 398-404
135. Chien H.H., Lin W.L., and Cho M.I. Expression of TGF-beta isoforms and their receptors during mineralized nodule formation by rat periodontal ligament cells in vitro. J Periodontal Res 34 (1999) 301-309
136. Teare J.A., Ramoshebi L.N., and Ripamonti U. Periodontal tissue regeneration by recombinant human transforming growth factor-beta3 in Papio ursinus. J Periodontal Res 43 (2008) 1-8
137. Lee B.S., and Nowak R.A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 86 (2001) 913-920
138. Gaide Chevronnay H.P., Cornet P.B., Delvaux D., Lemoine P., Courtoy P.J., Henriet P., et al. Opposite regulation of transforming growth factors-{beta}2 and -{beta}3 expression in the human endometrium. Endocrinology 149 (2008) 1015-1025
139. Al-Mowallad A., Carr T., Al-Qouzi A., Li C., Byers R., and Kumar S. Plasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia. Anticancer Res 26 (2006) 543-547
140. Yamamoto T., Akisue T., Marui T., Fujita I., Matsumoto K., Hitora T., et al. Expression of transforming growth factor beta isoforms and their receptors in malignant fibrous histiocytoma of soft tissues. Clin Cancer Res 10 (2004) 5804-5807
141. Zhang P.J., Goldblum J.R., Pawel B.R., Pasha T.L., Fisher C., and Barr F.G. PDGF-A, PDGF-Rbeta, TGFbeta3 and bone morphogenic protein-4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal desmoplasia: an immunohistochemical study. Mod Pathol 18 (2005) 382-387
142. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315 (1986) 1650-1659
143. Bissell M.J., and Radisky D. Putting tumours in context. Nat Rev Cancer 1 (2001) 46-54
144. Pedersen T.X., Leethanakul C., Patel V., Mitola D., Lund L.R., Danø K., et al. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. Oncogene 22 (2003) 3964-3976
145. Chang H.Y., Sneddon J.B., Alizadeh A.A., Sood R., West R.B., Montgomery K., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2 (2004) E7
146. Daopin S., Piez K.A., Ogawa Y., and Davies D.R. Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. Science 257 (1992) 369-373
147. Mittl P.R., Priestle J.P., Cox D.A., McMaster G., Cerletti N., and Grütter M.G. The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding. Protein Sci 5 (1996) 1261-1271
148. Wise E.L., Akana J., Gerlt J.A., and Rayment I. Structure of D-ribulose 5-phosphate 3-epimerase from Synechocystis to 1.6 A resolution. Acta Crystallogr D Biol Crystallogr 60 (2004) 1687-1690
149. Burgoyne N.J., and Jackson R.M. Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces. Bioinformatics 22 (2006) 1335-1342
150. Graycar J.L., Miller D.A., Arrick B.A., Lyons R.M., Moses H.L., and Derynck R. Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and -beta 2. Mol Endocrinol 3 (1989) 1977-1986
151. Cox DA, et al. Experimental wound healing studies with TGF beta. Wound Repair Regeneration 1994 2:S208.
152. Jacobsen S.E., Keller J.R., Ruscetti F.W., Kondaiah P., Roberts A.B., and Falk L.A. Bidirectional effects of transforming growth factor beta (TGF-beta) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-beta isoforms. Blood 78 (1991) 2239-2247
153. Jacobsen S.E., Ruscetti F.W., Roberts A.B., and Keller J.R. TGF-beta is a bidirectional modulator of cytokine receptor expression on murine bone marrow cells. Differential effects of TGF-beta 1 and TGF-beta 3. J Immunol 151 (1993) 4534-4544
154. James A.W., Xu Y., Lee J.K., Wang R., and Longaker M.T. Differential effects of TGF-beta1 and TGF-beta3 on chondrogenesis in posterofrontal cranial suture-derived mesenchymal cells in vitro. Plast Reconstr Surg 123 (2009) 31-43
155. Potts J.D., Dagle J.M., Walder J.A., Weeks D.L., and Runyan R.B. Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor beta 3. Proc Natl Acad Sci USA 88 (1991) 1516-1520
156. Nakajima Y., Mironov V., Yamagishi T., Nakamura H., and Markwald R.R. Expression of smooth muscle alpha-actin in mesenchymal cells during formation of avian endocardial cushion tissue: a role for transforming growth factor beta3. Dev Dyn 209 (1997) 296-309
157. Nguyen A.V., and Pollard J.W. Transforming growth factor beta3 induces cell death during the first stage of mammary gland involution. Development 127 (2000) 3107-3118
158. ten Dijke P., Iwata K.K., Goddard C., Pieler C., Canalis E., McCarthy T.L., et al. Recombinant transforming growth factor type beta 3: biological activities and receptor-binding properties in isolated bone cells. Mol Cell Biol 10 (1990) 4473-4479
159. Flanders K.C., Lüdecke G., Engels S., Cissel D.S., Roberts A.B., Kondaiah P., et al. Localization and actions of transforming growth factor-beta s in the embryonic nervous system. Development 113 (1991) 183-191
160. Lindholm D., Castrén E., Kiefer R., Zafra F., and Thoenen H. Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol 117 (1992) 395-400
161. Ren R.F., Lah J.J., Diehlmann A., Kim E.S., Hawver D.B., Levey A.I., et al. Differential effects of transforming growth factor-beta(s) and glial cell line-derived neurotrophic factor on gene expression of presenilin-1 in human post-mitotic neurons and astrocytes. Neuroscience 93 (1999) 1041-1049
162. Gorvy D.A., Herrick S.E., Shah M., and Ferguson M.W. Experimental manipulation of transforming growth factor-beta isoforms significantly affects adhesion formation in a murine surgical model. Am J Pathol 167 (2005) 1005-1019
163. Ask K., Bonniaud P., Maass K., Eickelberg O., Margetts P.J., Warburton D., et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol 40 (2008) 484-495